A patent review on the development of human cytochrome P450 inhibitors

Expert Opinion on Therapeutic Patents

Volumn 24, Issue 6, 2014, Pages 699-717

  Francis, Sheena ^a   Delgoda, Rupika ^a  

^a UNIVERSITY OF THE WEST INDIES   (Jamaica)

Author keywords

Antisteroidal; Azoles; Cancer; CYP; Drug metabolism; Monoclonal antibodies; Retinoic acid

Indexed keywords

ANTIBODY; ANTIDEPRESSANT AGENT; AROMATASE INHIBITOR; BENZENE; BENZOFURAN DERIVATIVE; CYTOCHROME P450 17; CYTOCHROME P450 1A2; CYTOCHROME P450 1B1; CYTOCHROME P450 26A1; CYTOCHROME P450 2A6; CYTOCHROME P450 2C; CYTOCHROME P450 2D6; CYTOCHROME P450 2E1; CYTOCHROME P450 3A; CYTOCHROME P450 3A4; CYTOCHROME P450 INHIBITOR; NATURAL PRODUCT; NONSTEROID ANTIINFLAMMATORY AGENT; PYRROLE DERIVATIVE; STEROID; STEROL 14ALPHA DEMETHYLASE;

BREAST CANCER; DERMATOLOGY; DRUG APPROVAL; DRUG INDICATION; DRUG INHIBITION; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; PATENT; PHARMACOGENETICS; PROSTATE CANCER; REVIEW; DRUG DEVELOPMENT; HUMAN;

CYTOCHROME P-450 ENZYME INHIBITORS; DRUG DISCOVERY; HUMANS; PATENTS AS TOPIC;

EID: 84901277549     PISSN: 13543776     EISSN: 17447674     Source Type: Journal    
DOI: 10.1517/13543776.2014.899583     Document Type: Review

References (100)

1. Lewis D, Ito Y. Cytochrome P450 structure and function: An evolutionary perspective. Royal Soc of Chemistry, UK; 2008
2. Isin EM, Guengerich FP. Complex reactions catalyzed by cytochrome P450 enzymes. Biochim Biophys Acta 2007;1770:314-29 (Pubitemid 46157073
3. Sligar SG, Makris TM, Denisov IG. Thirty years of microbial P450 monooxygenase research: Peroxoheme intermediates-The central bus station in heme oxygenase catalysis. Biochem Biophys Res Commun 2005;338:346-54 (Pubitemid 41541971
4. Gelboin HV, Gonzalez FJ, Yang TJ; Inventors. Agents that bind to and inhibit human cytochrome P450 1A2. US6335428; 2002
5. Melvin WA, Murray GIA; Inventors. Antibodies specific for CYP1B1. US7419794; 2008
6. Nishimura M, Yaguti H, Yoshitsugu H, et al. Tissue distribution of mRNA expression of human cytochrome P450 isoforms assessed by high-sensitivity real-Time reverse transcription PCR. Yakugaku Zasshi 2003;123:369-75 (Pubitemid 41327466
7. Tyndale RF. Genetic variation in CYP2A6-mediated nicotine metabolism alters smoking behavior. Ther Drug Monit 2002;24:163
8. Arinç E. The role of polymorphic cytochrome P450 enzymes in drug design, development and drug interactions with a special emphasis on phenotyping. J Mol Catal B-Enzym 2010;64:120-2
9. Gelboin HV, Gonzalez FJ; Inventors. Agents that bind to and inhibit human cytochrome P450 2A6. US6323325; 2001
10. Gelboin HV, Krausz KW, Gonzalez FJ; Inventors. Agents that bind to and inhibit human cytochrome P450 2C8, 2C9, 2C18 and 2C19. US6623960; 2003
11. Gelboin HV, Krausz KW, Gonzalez FJ; inventors. Antibodies that bind to and inhibit human cytochrome P450 2C9.1, 2C9.2, and 2C9.3. US7524939; 2009
12. Gelboin HV, Krausz KW, Gonzalez FJ; inventors. Agents that bind to and inhibit human cytochrome P450 2C19. US6908738; 2005
13. Cook Sangar M, Anandatheerthavarada HK, Tang W, et al. Human liver mitochondrial cytochrome P450 2D6-individual variations and implications in drug metabolism. FEBS J 2009;276:3440-53
14. Gelboin HV, Gonzalez FJ, Krausz KW; Inventors. Agents that bind to and inhibit human cytochrome P450 2D6. US6060253; 2000
15. Gelboin HV, Gonzalez FJ; Inventors. Inhibitory and non-inhibitory antigen binding polypeptides against human P450 enzymes. US5939530; 1999
16. Lu AY, Wang RW; Inventors. Anti-peptide antibody against human cytochrome P450 3A4. US6300476; 2001
17. Parise RA, Egorin MJ, Kanterewicz B, et al. CYP24, the enzyme that catabolizes the antiproliferative agent vitamin D, is increased in lung cancer. Int J Cancer 2006;119:1819-28 (Pubitemid 44356838
18. Jones G, Strugnell SA, Deluca HF. Current Understanding of the Molecular Actions of Vitamin D. Physiol Rev 1998;78:1193-231 (Pubitemid 28491953
19. Posner G, Kahraman M, Jeon HB, et al. Inventors. Low-calcemic oxime analogs of 1a,25-dihydroxy vitamin D3. US6982258; 2006
20. Posner GH, Crawford K, Yang HW, et al. Inventors. 24-Sulfur-substituted analogs of 1a,25-dihydroxy vitamin D3. US7166585; 2007
21. Kahraman M, Sinishtaj S, Dolan PM, et al. Potent, selective and low-calcemic inhibitors of CYP24 hydroxylase: 24-sulfoximine analogues of the hormone 1a,25-dihydroxyvitamin D3. J Med Chem 2004;47:6854-63 (Pubitemid 40053773
22. Stoppie P, Borgers M, Borghgraef P, et al. R115866 inhibits all-Trans-retinoic acid metabolism and exerts retinoidal effects in rodents. J Pharmacol Exp Ther 2000;293:304-12 (Pubitemid 30180953
23. Njar VC, Gediya L, Purushottamachar P, et al. Retinoic acid metabolism blocking agents (RAMBAs) for treatment of cancer and dermatological diseases. Bioorg Med Chem 2006;14:4323-40 (Pubitemid 43728662
24. Thatcher JE, Isoherranen N. The role of CYP26 enzymes in retinoic acid clearance. Expert Opin Drug Metab Toxicol 2009;5:875-86
25. Gomaa MS, Armstrong JL, Bobillon B, et al. Novel azolyl-(phenylmethyl)] aryl/ heteroarylamines: Potent CYP26 inhibitors and enhancers of alltrans retinoic acid activity in neuroblastoma cells. Bioorg Med Chem 2008;16:8301-13
26. Freyne E, Raeymaekers A, Venet M, et al. Synthesis of Liazal (TM), a retinoic acid metabolism blocking agent (RAMBA) with potential clinical applications in oncology and dermatology. Bioorg Med Chem Lett 1998;8:267-72 (Pubitemid 28066345
27. Vasudevan J, Johnson AT, Wang L, et al. Inventors. Compounds having activity as inhibitors of cytochrome P450RAI. US6252090; 2001
28. Vasudevan J, Johnson AT, Wang L, et al. Inventors. Compounds having activity as inhibitors of cytochrome P450RAI. US6399774; 2002
29. Johnson AT, Vasudevan J, Wang L, et al. Inventors. Compounds having activity as inhibitors of cytochrome P450RAI. US6369261; 2002
30. Vasudevan J, Johnson AT, Chandraratna RA; Inventors. Compounds having activity as inhibitors of cytochrome P450RAI. US6303785; 2001
31. Vasudevan J, Johnson AT, Wang L, et al. Inventors. Compounds having activity as inhibitors of cytochrome P450RAI. US6713647; 2004
32. Vasudevan J, Johnson AT, Wang L, et al. inventors. Compounds having activity as inhibitors of cytochrome P450RAI. US6387951; 2002
33. Vasudevan J, Johnson AT, Huang D, et al. Inventors. Compounds having activity as inhibitors of cytochrome P450RAI. US6369225; 2002
34. Njar VC, Brodie AM, Nnane IP; Inventors. C-4 substituted retinoids. US7265143; 2007
35. Johnson AT, Chandraratna RA. Novel retinoids with receptor selectivity and functional selectivity. Br J Dermatol 1999;140:12-17 (Pubitemid 29191432
36. Standeven AM, Johnson AT, Escobar M, et al. Specific Antagonist of Retinoid Toxicity in Mice. Toxicol Appl Pharmacol 1996;138:169-75 (Pubitemid 26160322
37. Patel JB, Mehta J, Belosay A, et al. Novel retinoic acid metabolism blocking agents have potent inhibitory activities on human breast cancer cells and tumour growth. Br J Cancer 2007;96:1204-15 (Pubitemid 46628615
38. Mccaffery P, Simons C. Prospective teratology of retinoic acid metabolic blocking agents (RAMBAs) and loss of CYP26 activity. Curr Pharm Des 2007;13:3020-37 (Pubitemid 350130968
39. Denis L, Debruyne F, De Porre P, et al. Early clinical experience with liarozole (Liazal-) in patients with progressive prostate cancer. Eur J Cancer 1998;34:469-75
40. Shiníchi Shimada S-G, Shin Nomoto K-G, Masayuki Okue S-G, et al. Inventors. Benzofuran derivatives. US6689798; 2004
41. Janssen MAC, Raeymaekers AHM, Freyne EJE, et al. Inventors. Pyrroloimidazolyl and imidazopyridinyl substituted 1H-benzimidazole derivatives. US5491161; 1996
42. Tasaka A, Hitaka T, Matsunaga N, et al. Inventors. Imidazole derivatives, production method thereof and use thereof. US7141598; 2006
43. Tasaka A, Matsunaga N, Ojida A, et al. Inventors. Imidazole derivatives, process for their preparation and their use. US6960586; 2005
44. Bock MG, Gaul C, Gummadi V, et al. Inventors. Inhibitors of CYP 17. US8263635; 2012
45. Brodie A, Njar V; Inventors. 17-Azolyl steroids useful as androgren synthesis inhibitors. US6200965; 2001
46. Handratta VD, Jelovac D, Long BJ, et al. Potent CYP17 inhibitors: Improved syntheses, pharmacokinetics and antitumor activity in the LNCaP human prostate cancer model. J Steroid Biochem Mol Biol 2004;92:155-65 (Pubitemid 39539227
47. Brodie A, Njar V; Inventors. C-17-heteroaryl steroidal CYP17 inhibitors/antiandrogens, in vitro biological activities, pharmacokinetics and antitumor activity. US7875599; 2011
48. Vasaitis T, Belosay A, Schayowitz A, et al. Androgen receptor inactivation contributes to antitumor efficacy of CYP17 inhibitor VN/124-1 in prostate cancer. Mol Cancer Ther 2008;7:2348
49. Vasaitis TS, Bruno RD, Njar VC. CYP17 inhibitors for prostate cancer therapy. J Steroid Biochem Mol Biol 2011;125:23-31
50. Barrie SE, Hardcastle IR, Jarman M, et al. Inventors. Method for preparing 17-substituted steroids useful in cancer treatment. US5618807; 1997
51. Jordan VC, Brodie AMH. Development and evolution of therapies targeted to the estrogen receptor for the treatment and prevention of breast cancer. Steroids 2007;72:7-25 (Pubitemid 46037765
52. Brodie A, Njar V, Macedo LF, et al. The Coffey Lecture: Steroidogenic enzyme inhibitors and hormone dependent cancer. Urol Oncol 2009;27:53-63
53. Thompson EA, Siiteri PK. Utilization of oxygen and reduced ricotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J Biol Chem 1974;249:5364-72
54. Tsuneo Kanamaru T, Tsuneaki Hida O, Masayuki Muroi S; Inventors. Physiologically active substance TAN-931, its derivatives, their production and use. US5196564; 1993
55. Ishii T, Hida T, Ishimaru T, et al. Tan-931 a novel nonsteroidal aromatase inhibitor produced by Penicillium funiculosum No. 8974. I, Taxonomy, fermentation, isolation, characterization and biological activities. J Antibiot (Tokyo) 1991;44:589-99
56. Bowman RM, Steele RE, Browne LJ; Inventors. Alpha-heterocycle substituted tolunitriles. EP0236940 B1; 1993
57. Bowman RM, Steele RE, Browne LJ; Inventors. Alpha-heterocycle substituted tolunitriles. US5071861; 1991
58. Differding E, Lang M, Stanek J; Inventors. 4-[a(cyanophenyl)-1-(1,2,3- Triazolyl)methyl]-benzonitrile. US5457209; 1995
59. Karjalainen AJ, Sodervall M-L, Kalapudas AM, et al. Inventors. Selective aromatase inhibiting compounds. US5703109; 1997
60. Okada M, Kawaminami E, Yoden T, et al. Inventors. Triazolylated tertiary amine compound or salt thereof. US5674886; 1997
61. Woo LWL, Sutcliffe OB, Bubert C, et al. First dual aromatase-steroid sulfatase inhibitors. J Med Chem 2003;46:3193-6 (Pubitemid 36842404
62. Gourvest J-F, Lesuisse D; Inventors 10-Thioethyl-steroids US5202314; 1993
63. Peet NP, Burkhart JP, Johnston JON; Inventors. Haloethyl-substituted steroid enzyme inhibitors. US5252565; 1993
64. Burkhart JP, Peet NP, Johnston JON; Inventors. Haloethyl-substituted steroidal enzyme inhibitors. EP 0450515 B1; 1995
65. Koizumi N, Takegawa S, Iwashita S, et al. Inventors. 7-substituted oxa-or azasteroid compound. US5539127; 1996
66. Koizumi N, Takegawa S, Iwashita S, et al. Inventors. Oxa-or azasteroid derivatives. US5519051; 1996
67. Koizumi N, Takegawa S, Iwashita ST, et al. Inventors. 7-Substituted oxasteroid compound. EP 0663402 B1; 1999
68. Koizumi N, Takegawa S, Iwashita S, et al. Inventors.-New D-homo-17-oxa and D-homo-17-Aza-Androstane derivatives. EP0582713 B1; 1997
69. Abul-Hajj YJ, Akanni A; Inventors. 6-Alkynyl steroids. US5866558; 1999
70. Reed MJ, Potter BVL; Inventors. Steroid sulphatase inhibitors. US6903084; 2005
71. Rodrigues AD. Drug-drug interactions. CRC Press, London; 2013
72. Francis S, Shields M, Jacobs H, Delgoda R. In-vitro assessment of chromones, alkaloids and other natural products from Caribbean plants as potential anti-Tuberculars and chemopreventors. In: Natural products: Structure, bioactivity and applications. Nova Publishers, New York; 2012
73. Hu OY-P, Hsiong C-H, Kuo BP-C, et al. Inventors. Cytochrome P450 3A inhibitors and enhancers. US7169763; 2007
74. Ren K, Lu X, Luo X; Inventors. Inhibition of CYP450 1A2, 2A6, 2C9, 2C19, 2D6, 2E1, and 3A4 in cryopreserved human hepatocytes by a Tripterygium Wilfordii Hook. F. extract. US7097865; 2006
75. Badal S, Williams SA, Huang G, et al. Cytochrome P450 1 enzyme inhibition and anticancer potential of chromene amides from Amyris plumieri. Fitoterapia 2011;82:230-6
76. Badal S, Delgoda R. Role of the modulation of CYP1A1 expression and activity in chemoprevention. J Appl Toxicol 2014;published online 14 February 2014; doi: 10.1002/jat.2968
77. He K, Hollenberg PF, Woolf TF; Inventors. Compositions containing Bergamottin for increasing the oral bioavailability of pharmaceutical agents. US6509371; 2003
78. Edwards DJ, Woster PM; Inventors. 6',7'-dihydroxybergamottin, a cytochrome P450 inhibitor in grapefruit. US6160006 A; 2000
79. Planken SP, Sutton SC, Chen R; Inventors. Therapeutic compounds. US7919488; 2011
80. Kempf DJ; Inventor. Compounds that are useful for improving pharmacokinetics. US8133892; 2012
81. Norbeck D, Kempf DJT, Leonard JM, et al. Inventors. Method for improving pharmacokinetics. US6037157; 2000
82. Norbeck D, Kempf DJT, Leonard JM, et al. Inventors. Method for improving pharmacokinetics. US6703403; 2004
83. Norbeck D, Kempf DJT, Leonard JM, et al. Inventors. Use of ritonavir (abt-538) for improving the pharmacokinetics of drugs metabolized by cytochrome P450 in a method of treating AIDS. EP0871465 B1; 2002
84. Woolf TF; Inventor. Nitrogen substituted acridine and cytochrome P450 inhibitors and methods of use. US5422350; 1995
85. Smith RA; Inventor. Use of a cytochrome oxidase inhibitor to increase the cough-suppressing activity of dextromorphan. US5350756; 1994
86. Walker KAM, Burton PM, Swinney DC; Inventors. 1,3-Dioxolane derivatives as cholesterol-lowering agents. EP0492474 B1; 1997
87. Zarn JA, Bruschweiler BJ, Schlatter Jr. Azole fungicides affect mammalian steroidogenesis by inhibiting sterol 14 alpha-demethylase and aromatase. Environ Health Perspect 2003;111:255-61 (Pubitemid 36395190
88. Treuner UD; Inventor. Aminoalkylphosphonic acid esters of natural 4-methoxy-5-methyl-pyran-3-ol and derivatives thereof. US5248790; 1993
89. Kirsch DR, O'sullivan J, Phillipson DW; Inventors. Scopularin. US5294725; 1994
90. Isin EM, Guengerich FP. Complex reactions catalyzed by cytochrome P450 enzymes. Biochim Biophys Acta 2007;1770:314-29 (Pubitemid 46157073
91. Delgoda R, Westlake ACG. Herbal interactions involving cytochrome P450 enzymes: A mini review. Toxicol Rev 2004;23:239-49 (Pubitemid 41018277
92. Lamb DC, Waterman MR, Kelly SL, et al. Cytochromes P450 and drug discovery. Curr Opin Biotechnol 2007;18:504-12
93. Buzzetti F, Barbugian N, Lombardi P, et al. Inventors. 6-substituted androsta-1,4-diene-3,17-diones. US4808616; 1989
94. Chow H-HS, Garland LL, Hsu C-H, et al. Resveratrol modulates drug-And carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev Res (Phila) 2010;3:1168-75
95. Anwar-Mohamed A, Zordoky BN, Aboutabl ME, et al. Alteration of cardiac cytochrome P450-mediated arachidonic acid metabolism in response to lipopolysaccharide-induced acute systemic inflammation. Pharmacol Res 2010;61:410-18
96. Mookherjee S, Acharya M, Banerjee D, et al. Molecular basis for involvement of CYP1B1 in MYOC upregulation and its potential implication in glaucoma pathogenesis. PLoS One 2012;7:e45077
97. Potter GA, Patterson LH, Burke MD; Inventors. Hydroxylation activated prodrugs. US6214886; 2001
98. Potter GA, Patterson LH, Burke MD; Inventors. Hydroxylation activated drug release. US20020037296 A1; 2002
99. Janssen MAC, Raeymaekers AHM, Freyne EJE, et al. Inventors. Pyrroloimidazolyl and imidazopyridinyl substituted 1h-benzimidazole derivatives as aromatase inhibitors. EP0625155 B1; 2001
100. Kaku T, Hitaka T, Ojida A, et al. Discovery of orteronel (TAK-700), a naphthylmethylimidazole derivative, as a highly selective 17,20-lyase inhibitor with potential utility in the treatment of prostate cancer. Bioorg Med Chem 2011;19:6383-99